Treatment of the acute respiratory distress syndrome (ARDS) with positive end-expiratory pressure (PEEP) was introduced more than 40 years ago. 1,2 Few practitioners question the effects of PEEP on hemoglobin saturation, but the optimal dose titration is controversial. Usually PEEP is simply adjusted to a suitable increase in oxygenation efficiency (i.e., the ratio of the partial pressure of arterial oxygen [PaO 2 ] to the fraction of inspired oxygen [FiO 2 ]) or according to an algorithm such as the Acute Respiratory Distress Syndrome Network (ARDSNet) protocol. 3 Because PEEP can impair cardiac output, some clinicians advocate titration to maximal oxygen delivery, a method that requires measurement of cardiac output. More complex techniques such as titration with the use of the pressure-volume relationship in the respiratory system have been reported. 4 In this issue of the Journal, Talmor and colleagues 5 describe a randomized trial of a mechanical-ventilation strategy in which PEEP was adjusted according to end-expiratory transpulmonary pressures (ClinicalTrials.gov number, NCT00127491). Transpulmonary pressure was measured as the difference between the airway opening pressure and the pleural pressure; pleural pressure was estimated from esophageal pressure. A small catheter with a balloon covering the holes at its end was used to measure pneumatic pressure in the esophagus. PEEP was then adjusted to produce an estimated transpulmonary pressure at end expiration of 0 to 10 cm of water, according to PaO 2 :FiO 2 . Originally designed to enroll 200 subjects, the trial was stopped by the safety board after only 61 subjects were enrolled. Termination was based on an a priori stopping rule requiring a difference in PaO 2 :FiO 2 between groups that was of a critical significance level (P<0.02).
Adjusting PEEP on the basis of transpulmonary pressure is a reasonable physiological premise, since this pressure is derived by calculating the difference between airway pressure and the highly variable pleural pressure. Pleural pressure can be unpredictable in cases of critical illness due to pleural effusion, elevated abdominal pressure, and variations in the elastance of the chest wall. For example, a large pleural effusion may raise pleural pressure, thereby reducing transpulmonary pressure at any given PEEP. However, accurate measurements of pleural pressure in the intensive care unit (ICU) are rarely possible. Because of this drawback, pleural pressure can be estimated only from esophageal pressure. The methods and limitations of estimating esophageal pressure have been published previously. 6, 7 In brief, many assumptions must be made in order to accept that pressure in the esophagus dynamically and accurately reflects pleural pressure. For instance, we must assume that the balloon pressure reflects the esophageal pressure, that the transmural pressure in the esophagus is 0 cm of water, that the esophagus is not compressed by intrathoracic structures such as the heart, that the pressures in the periesophageal area are the same as the pleural pressure, and that pleural pressure is relatively uniform throughout the thorax.
In fully one third of the patients in the study by Talmor et al., the balloon placement was inadequate, according to monitoring pressure recordings, and alternative placement techniques were used; this requirement calls into question the consistency of positioning and thus the reliability and reproducibility of the measurements. In addition, a correction factor of 5 cm of water was subtracted from the esophageal pressure in an attempt to compensate for the known artifacts of mediasti-n engl j med 359;20 www.nejm.org november 13, 2008 nal weight and balloon air volume on the observed pressures. However, the exact correction factor for this artifact is highly variable among even normal subjects, let alone the critically ill, and presents another potential source of error in using this estimate of pleural pressure. 6 It is also noteworthy that at least one subject could not be sedated sufficiently for balloon placement, and in another subject, obtaining readable tracings required extra sedation (see the data for Patient 3 in the Supplementary Appendix, available with the full text of the article by Talmor et al. at www. nejm.org), which may increase morbidity in this population. 8 On the basis of their previous work, 6 the authors could be fairly certain that using esophageal pressure to adjust PEEP would result in an increase in PEEP for most patients and would result in increased oxygenation efficiency. In this regard, the study was nicely designed and reasonably powered for the primary end point of increased PaO 2 :FiO 2 . The use of PaO 2 :FiO 2 as the outcome measure in this trial, since it is a derived variable, creates additional issues in interpreting the results. The investigators modified the ARDSNet protocol for the adjustment of PEEP and FiO 2 to allow a range for PaO 2 of 55 to 120 mm Hg, as compared with the standard 55 to 80 mm Hg. Table 2 in the article by Talmor et al. 5 shows that this range was relaxed even more in practice, since the mean (+SD) PaO 2 was 124+44 mm Hg in the esophageal-pressure-guided group at 72 hours (the time of the primary end point). Hence, it is likely that more than half the patients in the esophageal-pressure-guided group had a PaO 2 above the range stipulated by the protocol. This was not the case in the conventional-treatment group, in which the mean PaO 2 was only 101 mm Hg. Aside from issues related to protocol compliance, this difference in PaO 2 at the critical time of assessment for the primary outcome can create a profound artifact on PaO 2 :FiO 2 . 9 Therefore, it is unfortunate that the stopping rules were constructed around a noisy oxygenation end point instead of other outcomes. As the authors point out, the intriguing question of effects on important clinical outcomes such as long-term mortality, ventilator-free days, and length of stay in the ICU remain unanswered.
A discrepancy between oxygenation and clinical improvement in the end point has been observed previously. The only large trial to show a lowering of mortality rates in association with a particular method of ventilation also found that the group with improved oxygenation (the group with higher tidal volume) had higher mortality rates. 3 Thus, in my opinion, it is no longer acceptable to use oxygenation as a surrogate for improved clinical outcome. The ARDSNet Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate Lung Injury (ALVEOLI) trial compared higher PEEP with lower PEEP with the use of a standard protocol. 10 It and other studies showed that higher PEEP produced remarkable improvements in oxygenation yet no improvement in the rate of survival. 11,12 Interestingly, the cohorts in the ALVEOLI trial and the current study were fairly similar, but without direct measurements of pleural pressure, we cannot know for sure the transpulmonary pressures of the patients in either study. Tables  1 and 2 (Table 1) and at 72 hours (Table 2 ) was greater in the study by Talmor et al. The increase in PaO 2 :FiO 2 was also proportionately greater, suggesting that improvements in oxygenation in the study by Talmor et al. were reflective of generically higher PEEP, rather than a unique response to the PEEP titration method. Although the study by Talmor et al. is not sufficient to recommend a change in current practice, it has shown acceptable safety, and in the absence of a practical standard for pleural pressure, it seems reasonable to conduct further studies of this technique to assess feasibility and clinical benefit. Supported in part by the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network contracts (NO1-HR 46054 through 46064).
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